GLP-1 Prescriptions Quadrupled — And For The First Time, Obesity Rates Dropped
For years, the headline around obesity in America has been relentless growth. More people, higher BMI, more disease. The trajectory looked inevitable — up and to the right, year after year.
That may finally be changing.
New data from EPIC Research — which tracks more than 300 million patient records from thousands of hospitals and clinics across the country — shows GLP-1 prescriptions among U.S. adults have increased more than fourfold from Q2 2021 to Q1 2026, jumping from 1,884 to 8,919 prescriptions per 100,000 patients. And for the first time on record, the obesity rate in that same dataset declined: from 42% to 41%.
That’s not a rounding error. It’s a shift.
## What the Numbers Show
The EPIC COSMOS dataset covers over 300 million patient records, making it one of the most comprehensive real-world views of what’s happening in American health right now. The trend lines are clear:
– GLP-1 prescriptions: up >400% in five years
– Obesity prevalence: down one percentage point nationally — first decline in EPIC tracking history
– Largest BMI declines: seen in patients who had previously received GLP-1 medications
Gallup’s independent health index corroborated the finding: approximately 7.6 million fewer U.S. adults qualified as obese in 2025 compared to prior years. The two datasets tell the same story from different angles.
## Why This Matters
We’ve spent years debating whether GLP-1 medications actually work. The clinical trial data has always been strong — semaglutide, tirzepatide, and the rest produce meaningful weight loss. But clinical trials are controlled environments. Real-world population data is a different animal entirely.
This is that different animal.
When you see the effect showing up at the population level — across hundreds of millions of patient records, across thousands of clinical settings — that’s proof the drugs are working in the wild, not just in research protocols.
It also matters because it challenges the narrative that obesity is purely behavioral and untreatable with medication. The data says otherwise. More people are using these tools, and the population-level BMI numbers are finally moving in the right direction.
## What This Means for Denver
Colorado has historically tracked as one of the leanest states in the country — and EPIC’s dataset includes major Colorado health systems like UCHealth and Denver Health. The national decline in obesity mirrors what many Denver-area clinicians are observing in practice: more patients achieving meaningful, sustained weight loss with GLP-1 support.
The lesson here isn’t that medication alone solves obesity. Diet, activity, sleep, stress — all of it still matters. But when used as part of a comprehensive obesity medicine program, GLP-1s are producing results that are visible at the population level.
That’s new. And it’s worth noting.
—
Citation: EPIC Research, “GLP-1 Use Has More Than Quadrupled Since 2021 as Obesity Rates Continue to Show Signs of Decline,” published May 2026. Gallup Health Index, 2025.